Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice

Journal of Neural Transmission

Volumn 104, Issue 4-5, 1997, Pages 469-481

  Lan, J ^a,b   Jiang, D H ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

DFO; Iron; MPTP; Neurodegeneration; Vitamin E

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; ANTIOXIDANT; DEFEROXAMINE; DOPAMINE; FREE RADICAL; GLUTATHIONE; HYDROXYL RADICAL; IRON; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; IRON CHELATION; LIPID PEROXIDATION; MALE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BRAIN DISEASES; CORPUS STRIATUM; DEFEROXAMINE; DOPAMINE; FEMALE; GLUTATHIONE; GLUTATHIONE DISULFIDE; HYDROXYL RADICAL; IRON; LIPID PEROXIDES; MALE; MICE; NERVE DEGENERATION; OSMOLAR CONCENTRATION; VITAMIN E;

EID: 0030864433     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01277665     Document Type: Article

References (63)

1. Akai F, Maeda M, Hashimoto S, Taneda M, Takagi H (1995) A new animal model of cerebral infarction: magnetic embolization with carbonyl iron particles. Neurosci Lett 194: 139-141
2. Althaus JS, Andrus PK, Williams CM, Von Voigtlander PF, Gazers AR, Hall ED (1993) The use of salicylate hydroxylation to detect hydroxyl radical generation in ischemic and traumatic brain injury: reversal by tirilazad mesylate (U-74006F). Mol Chem Neuropath 20: 147-162
3. Andreoli SP, Cohen M (1989) Intraperitoneal desferrioxamine therapy for iron overload in children undergoing CAPD. Kidney Int 35: 1330-1335
4. Arendash GW, Sengstock GJ, Olanow CW, Barone S Jr, Dunn AJ (1994) Intranigral iron infusion as a model for Parkinson's disease. In: Woodruff ML, Nonneman AJ (eds) Toxin-induced models of neurological disorders. Plenum Press, New York, pp 175-212
5. Ben-Shachar D, Youdim MBH (1991a) Intranigral iron injection induces behavioral and biochemical parkinsonism in rats. J Neurochem 57: 2133-2135
6. Ben-Schachar D, Eshel G, Finberg JPM, Youdim MBH (1991b) The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56: 1441-1444
7. Ben-Schachar D, Eshel G, Riederer P, Youdim MBH (1992) Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for PD. Ann Neurol 32: S105-111
8. Cadet JL, Katz M, Jackson-Lewis V, Fahn S (1989) Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res 476: 10-15
9. Ceccarelli D, Gallesi D, Giovannini F, Ferrali M, Masini A (1995) Relationship between free iron level and rat liver mitochondrial dysfunction in experimental dietary iron overload. Biochem Biophy Res Commun 209: 53-59
10. Cohen A (1990) Current status of iron chelation therapy with desferrioxamine. Semin Hematol 27: 86-90
11. Cooper AJL, Pulsinelli WA, Duffy TE (1980) Glutathione and ascorbate during ischemia and postischemic reperfusion in rat brain. J Neurochem 35: 1242-1245
12. Crowe A, Morgan EH (1994) Effects of dictators on iron uptake and release by the brain in the rat. Neurochem Res 19: 71-76
13. Crowe A, Morgan EH (1996) Iron and copper interact during their uptake and deposition in the brain and other organs of developing rats exposed to dietary excess of the two metals. J Nutr 126: 183-194
14. Darley-Usmar VM, Hersey A, Garland LG (1989) A method for the comparative assessment of antioxidants as peroxyl radical scavengers. Biochem Pharmacol 38: 1465-1469
15. Denicola A, Souza JM, Gatti RM, Augusto O, Radi R (1995) Desferrioxamine inhibition of the hydroxyl radical-like reactivity of peroxynitrite: role of the hydroxamic groups. Free Radic Biol Med 19: 11-19
16. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring brain in Parkinson's disease. J Neurochem 52: 1830-1836
17. Dexter DT, Nanayakkara I, Goss-Sampson MA, Muller DPR, Harding AE, Marsden CD, Jenner P (1994) Nigral dopaminergic cell loss in vitamin E deficient rats. Neuroreport 5: 1773-1776
18. Erin AN, Spirin MM, Tabidze LV, Kagan VE (1984) Formation of tocopherol with fatty acids; a hypothetical mechanism of stabilization of biomembrane by vitamin E. Biochem Biophys Acta 774: 96-102
19. Fahn S (1992) A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 32 [Suppl]: 128-132
20. Floyd RA, Watson JJ, Wong PK (1984) Sensitive assay of hydroxyl free radical formation utilizing high pressure liquid chromatography with electrochemical detection of phenol and salicylate hydroxylation products. J Biochem Biophys Methods 10: 221-235
21. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative disease? J Neurochem 63: 793-807
22. Götz ME, Künig G, Riederer P, Youdim MBH (1994) Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63: 37-122
23. Halliwell B (1987) Oxidants and human disease: some new concepts. FASEB J 1: 358-364
24. Halliwell B (1989) Protection against tissue damage in vivo by desferrioxamine: what is mechanisms of action? Free Radic Biol Med 7: 645-651
25. Halliwell B, Gutteridge JM (1984) Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 219: 1-14
26. Halliwell B, Gutteridge JM (1986) Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys 246: 501-514
27. Hartley A, Davies M, Rice-Evans C (1990) Desferrioxamine as a lipid chain-breaking antioxidant in sickle erythrocyte membranes. FEBS Lett 264: 145-148
28. Ikeda Y, Ikeda K, Long DM (1989) Protective effect of the iron chelator deferoxamine on cold-induced brain edema. J Neurosurg 71: 233-238
29. Jenner P (1993) Altered mitochondria function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand 87 [Suppl 46]: 6-13
30. Keberle H (1964) The biochemistry of desferrioxamine and its relation to iron metabolism. Ann NY Acad Sci 119: 758-768
31. Kim C, Speisky MB, Kharouba SN (1987) Rapid and sensitive method for measuring norepinephrine, dopamine, 5-hydroxytryptamine and their major metabolites in rat brain by high-performance liquid chromatography. J Chromatogr 386: 25-35
32. Krause GS, Kumar K, Whilt BC, Aust SD, Wiegenstein JG (1986) Ischemia, resuscitation, and reperfusion: mechanisms of tissue injury and prospects for protection. Am Heart J 111: 768-780
33. Lin XM, Waller SB, Dietz NJ (1995) Effects of deferoxamine and a diet deficient in vitamin E on isoelectric electroencephalographic responses associated with ischemia by the four vessel occlusion method. Life Sci 57: 989-996
34. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275
35. Mizoi K, Suzuki J, Imazumi S, Yoshimoto T (1986) Development of new cerebral protective agents: the free radical scavengers. Neurol Res 8: 75-80
36. Odunze IN, Klaidman LK, Adams JD Jr (1990) MPTP toxicity in the mouse brain and vitamin E. Neurosci Lett 108: 346-349
37. Packer L, Landvik S (1990) Vitamin E in biological systems. Adv Exp Med Biol 264: 93-103
38. Parkinson Study Group (1989a) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321: 1364-1371
39. Parkinson Study Group (1989b) DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 46: 1052-1060
40. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328: 176-183
41. Perry TL, Yong VW, Clavier RM, Jones K, Wright JM, Foulks LG, Wall RA (1985) Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci Lett 60: 109-114
42. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520
43. Saunders RD, Dugan LL, Demediuk P, Means ED, Horrocks LA, Anderson DK (1987) Effects of methylprednisolone and the combination of α-tecopherol and selenium on arachidonic acid metabolism and lipid peroxidation in traumatized spinal cord tissue. J Neurochem 49: 24-31
44. Sengstock GJ, Olanow CW, Dunn AJ, Arendash GW (1992) Iron induces degeneration of nigrostriatal neurons. Brain Res Bull 28: 645-649
45. Sengstock GJ, Olanow CW, Menzies RA, Dunn AJ, Arendash GW (1993) Infusion of iron into the rat substantia nigra: nigral pathology and dose dependent loss of dopaminergic markers. J Neurosci Res 35: 67-82
46. Sengstock GJ, Olanow CW, Dunn AJ, Barone S Jr, Arendash GW (1994) Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra. Exp Neurol 130: 82-94
47. Sharma BK, Bacon BR, Britton RS, Park CH, Magiera CJ, O'Neill R, Dalton N, Smanik P. Speroff T (1990) Prevention of hepatocyte injury and lipid peroxidation by iron chelators and α-tocopherol in isolated iron loaded rat hepatocytes. Hepatology 12: 31-39
48. Sinaceur J, Ribiere C, Nordmann J, Nordmann R (1984) Desferrioxamine: a scavenger of superoxide radicals? Biochem Pharmacol 33: 1693-1694
49. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brain. J Neurochem 56: 978-982
50. Soriani M, Mazzuca S, Quaresima V, Minetti M (1993) Oxidation of desferrioxamine to nitroxide free radical by activited human neutrophils. Free Radic Biol Med 14: 589-599
51. Spina MB, Cohen G (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson's disease. Proc Natl Acad Sci USA 86: 1398-1400
52. Taylor E, Morgan E (1990) Developmental changes in transferrin and iron uptake by the brain in the rat. Dev Brain Res 55: 35-42
53. Tector AJ, Olynyk JK, Britton RS, Janney CG, O'Neill R, Bacon BR (1995) Hepatic mitochondrial oxidative metabolism and lipid peroxidation in iron-loaded rats fed ethanol. J Lab Clin Med 126: 597-602
54. Tietze F (1969) Enzymic method for quantitative determination of nanogram amount of total and oxidized glutathione. Anal Biochem 27: 502-522
55. Tsukamoto H, Home W, Kamimura S, Niemelä O, Parkkila S, Ylä-Herttuala S (1995) Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest 96: 620-630
56. Uchiyama M, Mihara M (1978) Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86: 271-278
57. Uitti RJ, Rajput AH, Rozdilsky B, Bickis M, Wollin T, Yuen WK (1989) Regional metal concentrations in Parkinson's disease, other chronic neurological disease, and control brains. Can J Neurol Sci 16: 310-314
58. Vatassery GT, Brin MF, Fahn S, Kayden HJ, Traber MG (1988) Effect of high doses of dietary vitamin E on the concentrations of vitamin E in several brain regions, plasma, liver, and adipose tissue of rats. J Neurochem 51: 621-623
59. Ward RJ, Dexter D, Florence A, Aouad F, Hider R, Jenner P, Crichton R (1995) Brain iron in the ferrocene-loaded rat: its chelation and influence on dopamine metabolism. Biochem Pharmacol 49: 1821-1826
60. Wolfe L, Olivier N, Sallau D (1985) Prevention of cardiac disease by subcutaneous desferrioxamine in patients with thalassemia major. N Engl J Med 312: 1600-1604
61. Youdim MBH, Ben-Shachar D, Eshel G, Finberg JPM, Riederer P (1993) The neurotoxicity of iron and nitric oxide: relevance to the etiology of Parkinson's disease. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (eds) Advances in neurology. Raven Press, New York, pp 259-266
62. Zecca L, Pietra R, Goj C, Mecacci C, Radice D, Sabbioni E (1994) Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J Neurochem 62: 1097-1101
63. Zigmond MJ, Aberombie ED, Berger TW, Grace AA, Stricker EM (1990) Compensation after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13: 290-295